Treatment of cancer-related hypercalcemia: The role of gallium nitrate

Seminars in Oncology

Volumn 30, Issue 2 SUPPL. 5, 2003, Pages 13-19

  Leyland Jones, Brian ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; DIURETIC AGENT; ETIDRONIC ACID; GALLIUM NITRATE; MITHRAMYCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BLEEDING TENDENCY; BONE PAIN; BRADYCARDIA; CALCIFICATION; CANCER; CLINICAL FEATURE; CLINICAL TRIAL; DEHYDRATION; DRUG EFFICACY; DRUG MECHANISM; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY FAILURE; LIVER TOXICITY; NAUSEA; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; POLYURIA; PRIORITY JOURNAL; REVIEW; TACHYPHYLAXIS; TREATMENT OUTCOME; URINARY EXCRETION; VOMITING;

ANTINEOPLASTIC AGENTS; GALLIUM; HUMANS; HYPERCALCEMIA; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0038147472     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00171-4     Document Type: Review

References (30)

1. Lang-Kummer J: Hypercalcemia, in Yarbro CH, Frogge MH, Goodman M, Groenwald SL, (eds): Cancer Nursing: Principles and Practice (ed 4). Sudbury, MA, Jones and Bartlett, 1997 pp 684-701
2. Guise TA, Mundy GR: Cancer and bone. Endocr Rev 19:18-54, 1998
3. Warrell RP Jr: Metabolic emergencies, in DeVita VT Jr, Hellman S, Rosenberg SA, (eds): Cancer: Principles & Practice of Oncology (ed 6). Philadelphia, PA, Lippincott, Williams & Wilkins, 2001, pp 2633-2634
4. Strewler GJ, Neissenson RA: Nonparathyroid hypercalcemia. Adv Intern Med 32:235-258, 1987
5. Lamy O, Jenzer-Closuit A, Burckhard P: Hypercalcaemia of malignancy: An undiagnosed and undertreated disease. J Intern Med 250:73-79, 2001
6. Stewart AF, Horst R, Deftos LJ, et al: Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and non-humoral groups. N Engl J Med 303:1377-1383, 1980
7. Graham WP III, Gardner B, Thomas AN, et al: Hypercalcaemia in carcinoma of the female breast. Surg Gynecol Obstet 117:709-714, 1963
8. Ralston SH, Fogelman I, Gardiner MD, et al: Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. BMJ 288:1405-1408, 1984
9. Casez J, Pfammatter R, Nguyen Q, et al: Diagnostic approach to hypercalcemia: Relevance of parathyroiod hormone and parathyroid hormone-related protein measurements. Eur J Intern Med 12:344-349, 2001
10. Burtis WJ, Brady TG, Orloff JJ, et al: Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322:1106-1112, 1990
11. Mundy GR: Pathophysiology of cancer-associated hypercalcemia. Semin Oncol 17:10-15, 1990 (suppl 5)
12. Heys SD, Smith IC, Eremin O: Hypercalcaemia in patients with cancer: Aetiology and treatment. Eur J Surg Oncol 24:139-142, 1998
13. Davidson TG: Conventional treatment of hypercalcemia of malignancy. Am J Health Syst Pharm 58:S8-S15, 2001 (suppl 3)
14. Hosking DJ, Cowley A, Bucknell CA: Rehydration in the treatment in severe hypercalcemia. QJ Med 200:473-481, 1981
15. Thalassinas NC, Joplin GF: Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease. Lancet 2:537-538, 1970
16. Zoyer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcemia of malignancy. Drug Saf 21:389-406, 1999
17. Gucalp R, Ritch P, Wiernik PH, et al: Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10: 134-142, 1992
18. Kanis JA, McCloskey EV: Clodronate. Cancer 80:1691-1695, 1997
19. O'Rourke NP, McCloskey EV, Vasikaran S, et al: Effective treatment of malignant hypercalcemia with a single intravenous infusion of clodronate. Br J Cancer 67: 560-563, 1993
20. Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567, 2001
21. Walls J, Ratcliffe WA, Howell A, et al: Response to intravenous bisphosphonate therapy in hypercalcemic patients with and without bone metastases: The role of parathyroid hormone-related protein. Br J Cancer 70:169-172, 1994
22. Wimalawansa SJ: Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 73:2223-2230, 1994
23. Warrell RP, Israel R, Frisone M, et al: Gallium nitrate for acute treatment of cancer-related hypercalcemia. Ann Intern Med 108:669-674, 1988
24. Wisneski LA: Salmon calcitonin in the acute management of hypercalcemia. Calicif Tissue Int 46:S26-S30, 1990
25. Warrell RP, Bockman RS, Coonley CJ, et al: Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 73:1487-1490, 1984
26. Bockman RS: Studies on the mechanism of action of gallium nitrate. Semin Oncol 18: 21-25, 1991 (suppl 5)
27. Bertheault-Cvitkovic F, Armand J-P, Tubiana-Hulin M, et al: Randomized, double-blind comparison of pamidronate vs. gallium nitrate for acute control of cancer-related hypercalcemia. Presented at the 9th EORTC/NC1 Symposium, Amsterdam, March 1996
28. Warrell RP, Murphy WK, Schulman P, et al: A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 9:1467-1475, 1991
29. Budayr AA, Nissenson RA, Klein RF, et al: Increased serum levels of a parathyroid hormone-like protein in malignancyassociated hypercalcemia. Ann Intern Med 111:807-812, 1989
30. Henderson JE, Shustik C, Kremer R, et al: Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. J Bone Miner Res 5:105-113, 1990